All In Biotech

Drug Trial Radar · NCT02608476

A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (26)

A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris

Last checked: Nov 19, 2026Latest source record: Nov 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 732 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

732

Actual

Start

Nov 16, 2015

Primary completion

Feb 21, 2018

Study completion Feb 21, 2018

Sponsor

Lead sponsor
Cassiopea SpAIndustry
Sponsor type
Industry
First posted
Nov 18, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 9 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to determine the safety and efficacy of CB-03-01 cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

  • CB-03-01 cream, 1%Drug

    CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.

  • Vehicle creamDrug

    Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA)Time frame: Week 12
  2. Change From Baseline in Non-inflammatory Lesion (NIL) CountsTime frame: Baseline and Week 12
  3. Change From Baseline in Inflammatory Lesion (IL) CountsTime frame: Baseline and Week 12

Locations

52 sites in 6 countries. Site status is shown where the registry gives one.

  • Clear dermatology & Aesthetic Center

    Scottsdale, Arizona

  • Johnson Dermatology

    Fort Smith, Arkansas

  • Center for Dermatology and Laser Surgery

    Sacramento, California

  • Belleair Research Center

    Pinellas Park, Florida

  • Arlington Dermatology

    Arlington Heights, Illinois

  • Kansas City Dermatology, PA

    Overland Park, Kansas

  • Maryland Laser Skin and Vein Institute

    Hunt Valley, Maryland

  • Sadick Research Group, LLC

    New York, New York

  • Skin Specialty Dermatology

    New York, New York

  • Clinical Partners, LLC

    Johnston, Rhode Island

  • Texas Dermatology and Laser Specialists

    San Antonio, Texas

  • Progressive Clinical Research, PA

    San Antonio, Texas

  • Site 3521

    Plovdiv, Bulgaria

  • Site 3523

    Sofia, Bulgaria

  • Site 3525

    Sofia, Bulgaria

  • 3520

    Sofia, Bulgaria

  • Site 3524

    Sofia, Bulgaria

  • Site 3519

    Sofia, Bulgaria

  • Site 3526

    Sofia, Bulgaria

  • Site 3522

    Varna, Bulgaria

  • Site 9923

    Batumi, Georgia

  • Site 9924

    Kutaisi, Georgia

  • Site 9921

    Tbilisi, Georgia

  • Site 9920

    Tbilisi, Georgia

  • Site 9922

    Tbilisi, Georgia

  • Site 9925

    Zugdidi, Georgia

  • 4819

    Bydgoszcz, Poland

  • Site 4814

    Częstochowa, Poland

  • Site 4822

    Częstochowa, Poland

  • 4815

    Katowice, Poland

  • Site 4811

    Katowice, Poland

  • Site 4821

    Krakow, Poland

  • Site 4815

    Krakow, Poland

  • Site 4813

    Krakow, Poland

  • Site 4820

    Lodz, Poland

  • Site 4823

    Osielsko, Poland

  • Site 4816

    Rzeszów, Poland

  • Site 4812

    Szczecin, Poland

  • Site 4818

    Warsaw, Poland

  • Site 4036

    Bucharest, Romania

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.